The report highlights Eurofarma's commitment to sustainable growth and social responsibility. The company achieved a 14% growth in revenue in 2023, with an adjusted EBITDA margin of 25.1%. Eurofarma also expanded its global footprint, acquiring Genfar's operations in Colombia, Peru, and Ecuador. The report also highlights the company's investments in innovation, with R$615 million invested in R&D in 2023. Eurofarma also made significant investments in its social responsibility programs, including the Eurofarma Institute, which provides quality education to socioeconomically vulnerable children and young adults in Brazil. The company also launched the Lactare breast milk bank, which has partnered with eight public hospitals in Brazil. The report also highlights the company's commitment to environmental sustainability, with a focus on reducing greenhouse gas emissions and expanding the use of renewable energy. Eurofarma also invested R$8 million in the purchase of eco-efficient cooling equipment in 2023.
